Heart drug mavacamten shows promise in thick heart muscle disease

This study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and blocks blood flow. Researchers compared those who took the drug mavacamten to those on standard therapy. The main goal was to see if mavacamten could reduce the pressure gradient across the heart's main pumping chamber after 30 weeks. The study provides real-world evidence on how well the drug works and its safety in Chinese patients.